Sweeny Nicole 4

What Happened
Nicole Sweeny, Chief Commercial Officer of KalVista Pharmaceuticals, was granted 100,000 restricted stock units (RSUs) on 2026-01-16. The grant is reported as a derivative award with a reported acquisition price of $0.00 (RSUs represent contingent rights to receive common stock for no cash consideration upon settlement). This is an equity compensation award, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-01-16; Grant type: Award/Grant (code A); Price: $0.00 per RSU.
• Number of RSUs granted: 100,000 (each RSU = contingent right to 1 share upon settlement).
• Shares owned after transaction: not specified in the provided filing.
• Vesting: 1/16th of the total RSUs vest on each quarterly anniversary beginning May 22, 2026 (i.e., vesting occurs quarterly over 16 quarters / ~4 years), contingent on continued service.
• Filing date: Form filed 2026-01-21 for the 2026-01-16 grant. The provided data does not include a late-filing flag; check official EDGAR record for timeliness details.

Context
RSUs are a common form of employee equity compensation; they do not require the grantee to pay cash and only convert to actual shares when vested/settled. Because this is an award (not a purchase or sale), it is primarily compensation-related information rather than a direct signal of the insider’s market view.